[MH6] Modelling the costs of illness and the costs of relapse in the management of schizophrenia in the UK

[MH6] Modelling the costs of illness and the costs of relapse in the management of schizophrenia in the UK

2001 Value in health

Launois, R. | Presente, G. | Hansen, K. | Toumi, M. | Volume: 4, Issue: 6, Pages: 416, S,

OBJECTIVE: Schizophrenia is probably one of the most
costly mental-health illnesses in terms of its impact on the
society, on the health-care system and on patients and
their families. We aim to develop a framework for analyzing
schizophrenia through the estimation of the costs
of illness as well as the costs of relapse in the management
of schizophrenia in a UK care setting.
METHODS: A model that utilizes a Markov structure was
elaborated in order to calculate the lifetime cost of illness
and the principal cost driver in schizophrenia, the cost of
relapse. The model included the main confounding factors
such as compliance, dropout, and treatment location,
which have been shown to be important in the literature
when constructing a model. The costs were estimated for a
10-year period as well as for the lifetime of a patient, and
consider all types of treatment structures in the UK.
RESULTS: The average 10-year cost of illness for a patient
in a UK treating environment was estimated at £ 66 600,
and the lifetime cost per patient at £ 98 510. As for the cost
of relapse of a schizophrenic patient, the 10-year cost was
£ 51 630 and the lifetime cost per patient was £ 75 890.
CONCLUSIONS: This model enables the identification
and the calculation of the main cost drivers in the treatment
of schizophrenia. This model can therefore be used
to evaluate the cost implication of treatment options and
policy choices, by generating budgetary provisions. Hence,
this model can help decision-makers in policy-making for
mental health-care organizations in the management of
schizophrenia.

https://www.doi.org/10.1016/S1098-3015(11)71525-X